ストックスクリーナーアプリを入手
1.18
0.00%
0.00
アフターアワーズ：
1.16
-0.02
-1.69%
Theriva Biologics Inc (TOVX) 最新ニュース
Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq
Theriva™ Biologics Announces Positive Outcomes from the - GlobeNewswire
Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan
Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World
Theriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New Orleans - Nasdaq
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewswire
Cancer Therapeutics Innovator Theriva Set for Major Presentation at NeauxCancer 2025 - Stock Titan
Theriva Biologics Reports 2024 Financial Results and Progress - TipRanks
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - The Manila Times
Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? - StockTitan
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - The Manila Times
Cancer Therapeutics Company Theriva Sets Key Investor Presentation DateWhat to Expect - StockTitan
Theriva Biologics Inc Inc. (TOVX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst - Benzinga
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga
Synthetic Biologics stock hits 52-week low at $1.21 - Investing.com India
Synthetic Biologics stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
Theriva Biologics outlines Phase 3 study for cancer drug By Investing.com - Investing.com Canada
Theriva™ Biologics Announces U.S. FDA Guidance on Design of - GlobeNewswire
Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment - StockTitan
Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
Synthetic Biologics stock hits 52-week low at $1.24 - Investing.com
Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World
Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks
Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
What's Going On With Theriva Biologics Stock Friday? - MSN
Theriva Biologics Expands Stock Plans and Share Authority - TipRanks
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - The Manila Times
Theriva Biologics gains EU orphan drug status for eye cancer treatment - Investing.com
Theriva Biologics Announces Orphan Medicinal Product - GlobeNewswire
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - StockTitan
Check out these key findings about Theriva Biologics Inc (TOVX) - SETE News
Theriva Biologics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Was Theriva Biologics Inc (TOVX)’s session last reading good? - US Post News
Market cap of Theriva Biologics Inc [TOVX] reaches 4.06M – now what? - The DBT News
Closing Figures: Theriva Biologics Inc (TOVX)’s Positive Finish at 1.79, Up 44.35 - The Dwinnex
Theriva reports progress in phase 1b/2a trial of SYN-004 By Investing.com - Investing.com South Africa
Synthetic Biologics stock plunges to 52-week low of $1.24 By Investing.com - Investing.com Australia
Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients - Seeking Alpha
Theriva Biologics Advances SYN-004 in Clinical Trial - TipRanks
Theriva reports progress in phase 1b/2a trial of SYN-004 - Investing.com India
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Manila Times
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):